Literature DB >> 28074529

Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.

Ercan Cacan1.   

Abstract

The immunological response against cancer is a critical balance between immune-activating and immune-suppressing mechanisms. Ovarian cancer creates a suppressive microenvironment to escape immune elimination; however, the molecular mechanisms are poorly understood, and it is unclear whether chemotherapeutic drugs exert an immunoreactive or immunosuppressive effect on the tumor microenvironment. 4-1BB ligand (4-1BBL/CD157) and OX-40 ligand (OX-40L/CD252) are important regulators of effector cytotoxic T-cells activity. This study demonstrates that expression of positive co-stimulatory molecules, OX-40L and 4-1BBL, is suppressed while expression of immunosuppressive molecule programmed death ligand-1 (PD-L1/CD274) is enhanced in chemoresistant cells compared to parental chemosensitive ovarian cancer cells. Here, the molecular mechanisms of silencing of OX-40L and 4-1BBL expression were investigated in chemoresistant A2780-AD ovarian cancer cells. The suppression of OX-40L and 4-1BBL are due to DNA hypermethylation and histone deacetylation, two important mechanisms that contribute to gene silencing during cancer progression. We identify important epigenetic regulators, histone deacetylase 1/3 (HDAC1/HDAC3) and DNA methyltransferase 1 (DNMT1), that exhibit aberrant association with OX-40L and 4-1BBL promoters in chemoresistant ovarian cancer cells. Knockdown of HDAC1 or DNMT1 expression, and pharmacological inhibition of DNMT or HDAC enzymatic activity, significantly increase OX-40L and 4-1BBL expression in chemoresistant cells. This study suggests that loss of histone acetylation and accumulation of DNA methylation correlates with suppressed expression of OX-40L and 4-1BBL in chemoresistant ovarian cancer cells. This study marks the first report of the regulation of these two molecules by histone deacetylation and DNA methylation in chemoresistant ovarian cancer cells.
© 2017 International Federation for Cell Biology.

Entities:  

Keywords:  chemoresistance; co-stimulatory molecules; epigenetics; immune suppression; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28074529     DOI: 10.1002/cbin.10729

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  11 in total

Review 1.  Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

Authors:  Julie L Hentze; Claus K Høgdall; Estrid V Høgdall
Journal:  Mol Clin Oncol       Date:  2019-01-11

2.  Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: prognosis and influence of tumor microenvironment.

Authors:  Lin-Hui Yang; Li-Zhen Xu; Zhi-Jian Huang; Hong-Hong Pan; Min Wu; Qiu-Yan Wu; Tao Lu; Yan-Ping Zhang; Yao-Bin Zhu; Jia-Bin Wu; Jie-Wei Luo; Guo-Kai Yang; Lie-Fu Ye
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.

Authors:  Peng Ding; Zhiqiang Ma; Dong Liu; Minghong Pan; Huizi Li; Yingtong Feng; Yimeng Zhang; Changjian Shao; Menglong Jiang; Di Lu; Jing Han; Jinliang Wang; Xiaolong Yan
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 4.  Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments.

Authors:  Javier Martinez-Useros; Mario Martin-Galan; Maria Florez-Cespedes; Jesus Garcia-Foncillas
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

5.  Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels.

Authors:  Deepika Nair; Emelie Rådestad; Prajakta Khalkar; Nuria Diaz-Argelich; Axel Schröder; Charlotte Klynning; Johanna Ungerstedt; Michael Uhlin; Aristi P Fernandes
Journal:  Front Oncol       Date:  2018-09-28       Impact factor: 6.244

Review 6.  Epigenetics in ovarian cancer: premise, properties, and perspectives.

Authors:  Qilian Yang; Yuqing Yang; Nianxin Zhou; Kexin Tang; Wayne Bond Lau; Bonnie Lau; Wei Wang; Lian Xu; Zhengnan Yang; Shuang Huang; Xin Wang; Tao Yi; Xia Zhao; Yuquan Wei; Hongjing Wang; Linjie Zhao; Shengtao Zhou
Journal:  Mol Cancer       Date:  2018-07-31       Impact factor: 27.401

7.  Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.

Authors:  Sara Moufarrij; Aneil Srivastava; Stephanie Gomez; Melissa Hadley; Erica Palmer; Paul Tran Austin; Sarah Chisholm; Noor Diab; Kyle Roche; Angela Yu; Jing Li; Wenge Zhu; Micael Lopez-Acevedo; Alejandro Villagra; Katherine B Chiappinelli
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

8.  Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.

Authors:  Chen Zhang; Qing Yang
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

9.  The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin.

Authors:  Xi-Wen Wang; Qi-Qiang Guo; Yang Yu; Ting-Ting Zhou; Si-Yi Zhang; Zhuo Wang; Jing-Wei Liu; Jun Tang; Xiao-You Jiang; Shan-Shan Wang; Wen-Dong Guo; Hong-de Xu; Hua-Yi Sun; Zi-Wei Li; Xiao-Yu Song; Jun-Gang Zhao; Liu Cao
Journal:  J Cell Mol Med       Date:  2021-12-06       Impact factor: 5.310

Review 10.  Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.

Authors:  Carolina Maria Sassu; Innocenza Palaia; Serena Maria Boccia; Giuseppe Caruso; Giorgia Perniola; Federica Tomao; Violante Di Donato; Angela Musella; Ludovico Muzii
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.